PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29409752-4	2018	Herein, we report the design of receptor-interacting protein kinase 2 (RIPK2) inhibitors based on pan-kinase inhibitor regorafenib that aim to engage basic activation loop residues Lys169 or Arg171.	regorafenib	119-130	receptor interacting serine/threonine kinase 2	Homo sapiens	32-69	
26320862-3	2015	The most potent RIPK2 inhibitors were the US Food and Drug Administration-approved drugs ponatinib and regorafenib.	regorafenib	103-114	receptor interacting serine/threonine kinase 2	Homo sapiens	16-21	
29409752-4	2018	Herein, we report the design of receptor-interacting protein kinase 2 (RIPK2) inhibitors based on pan-kinase inhibitor regorafenib that aim to engage basic activation loop residues Lys169 or Arg171.	regorafenib	119-130	receptor interacting serine/threonine kinase 2	Homo sapiens	71-76